EyeGate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference
24 janv. 2017 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 24, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Awarded Canadian Patent for Proprietary Iontophoretic Formulation and Use of the Formulation for Ocular Delivery of Dexamethasone Phosphate
23 janv. 2017 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and...
EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437
09 janv. 2017 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Reports Positive Data from Third Stage of Phase 1b/2a Clinical Trial of EGP-437 in Cataract Surgery Patients
05 déc. 2016 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
FDA Confirms a 510(k) De Novo Path for EyeGate’s Device, the Ocular Bandage Gel, Following Pre-Submission Meeting
17 nov. 2016 16h01 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
02 nov. 2016 09h20 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference
21 sept. 2016 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG), (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense
13 sept. 2016 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 13, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437
12 sept. 2016 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharmaceuticals to Present at the 18th Annual Rodman and Renshaw Global Investment Conference
06 sept. 2016 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- EYEG (Nasdaq:EYEG), (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products...